Overview

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is a study in healthy subjects. There are two parts to the study. In the first part of the study each subject will receive a single 10mg dose of each of the four formulations of E550. Based on the results from Part 1, an optimal formulation will be selected for further evaluation in Part 2.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Pharmaceutical Solutions